Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-11-25 4:29 pm Purchase | 2025-11-19 | 13G | Entrada Therapeutics, Inc. TRDA | TCG Crossover GP I, LLC | 1,917,344 5.000% | 1,917,344 (New Position) | Filing History |
| 2025-11-18 4:38 pm Sale | 2025-11-14 | 13D | Entrada Therapeutics, Inc. TRDA | 5AM Ventures V, L.P. | 4,123,849 10.800% | -285,838 (-6.48%) | Filing History |
| 2025-11-14 12:19 pm Sale | 2025-09-30 | 13G | Entrada Therapeutics, Inc. TRDA | T. Rowe Price Associates, Inc. | 360,526 0.900% | -2,206,952 (-85.96%) | Filing History |
| 2025-08-14 1:07 pm Sale | 2025-06-30 | 13G | Entrada Therapeutics, Inc. TRDA | T. Rowe Price Associates, Inc. | 2,567,478 6.800% | -482,094 (-15.81%) | Filing History |
| 2025-08-14 10:46 am Sale | 2025-06-30 | 13G | Entrada Therapeutics, Inc. TRDA | JANUS HENDERSON GROUP PLC JHG | 1,521,281 4.000% | -600,373 (-28.30%) | Filing History |
| 2025-05-14 12:28 pm Purchase | 2025-03-31 | 13G | Entrada Therapeutics, Inc. TRDA | JANUS HENDERSON GROUP PLC JHG | 2,121,654 5.600% | 41,287 (+1.98%) | Filing History |
| 2025-02-14 3:47 pm Sale | 2024-12-31 | 13G | Entrada Therapeutics, Inc. TRDA | Roche Finance Ltd | 2,569,115 6.900% | -175,005 (-6.38%) | Filing History |
| 2025-02-14 11:25 am Purchase | 2024-12-31 | 13G | Entrada Therapeutics, Inc. TRDA | JANUS HENDERSON GROUP PLC JHG | 2,080,367 5.600% | 2,080,367 (New Position) | Filing History |
| 2025-02-04 3:45 pm Purchase | 2024-12-31 | 13G | Entrada Therapeutics, Inc. TRDA | BlackRock Inc. BLK | 1,974,452 5.300% | 1,974,452 (New Position) | Filing History |
| 2024-11-14 1:22 pm Purchase | 2024-09-30 | 13G | Entrada Therapeutics, Inc. TRDA | T. Rowe Price Associates, Inc. | 3,049,572 8.200% | 39,899 (+1.33%) | Filing History |
| 2024-06-26 4:54 pm Purchase | 2024-06-24 | 13D | Entrada Therapeutics, Inc. TRDA | Baker Bros. Advisors LP | 4,865,819 13.200% | 161,400 (+3.43%) | Filing History |
| 2024-02-14 4:26 pm Sale | 2023-12-31 | 13G | Entrada Therapeutics, Inc. TRDA | Redmile Group, LLC | 1,283,735 3.800% | -570,373 (-30.76%) | Filing History |
| 2024-02-14 4:12 pm Sale | 2023-12-31 | 13G | Entrada Therapeutics, Inc. TRDA | Roche Finance Ltd | 2,744,120 8.200% | -69,405 (-2.47%) | Filing History |
| 2024-02-14 10:03 am Sale | 2023-12-31 | 13G | Entrada Therapeutics, Inc. TRDA | T. Rowe Price Associates, Inc. | 3,009,673 9.000% | -4,704 (-0.16%) | Filing History |
| 2023-02-14 4:25 pm Sale | 2022-12-31 | 13G | Entrada Therapeutics, Inc. TRDA | Redmile Group, LLC | 1,854,108 5.900% | -100,312 (-5.13%) | Filing History |
| 2023-02-14 12:38 pm Purchase | 2022-12-31 | 13G | Entrada Therapeutics, Inc. TRDA | T. Rowe Price Associates, Inc. | 3,014,377 9.600% | 993,740 (+49.18%) | Filing History |
| 2023-02-06 2:51 pm Sale | 2022-12-30 | 13G | Entrada Therapeutics, Inc. TRDA | Wellington Management Group LLP | 1,010,351 3.220% | -2,103,655 (-67.55%) | Filing History |
| 2022-02-14 5:07 pm Purchase | 2021-12-31 | 13G | Entrada Therapeutics, Inc. TRDA | Redmile Group, LLC | 1,954,420 6.300% | 1,954,420 (New Position) | Filing History |
| 2022-02-14 2:35 pm Purchase | 2021-12-31 | 13G | Entrada Therapeutics, Inc. TRDA | T. Rowe Price Associates, Inc. | 2,020,637 6.400% | 2,020,637 (New Position) | Filing History |
| 2022-02-14 06:19 am Purchase | 2021-12-31 | 13G | Entrada Therapeutics, Inc. TRDA | Roche Finance Ltd | 2,813,525 9.000% | 2,813,525 (New Position) | Filing History |